Prostate cancer: Making the switch from LHRH antagonist to LHRH agonist

Nature Reviews Urology

Volumn 9, Issue 3, 2012, Pages 125-126

  Moul, Judd W ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABARELIX; DEGARELIX; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GOSERELIN; KETOCONAZOLE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

CANCER LOCALIZATION; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATIGUE; HOT FLUSH; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SHORT SURVEY; THEORY;

CLINICAL TRIALS AS TOPIC; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; MALE; OLIGOPEPTIDES; PROSTATIC NEOPLASMS;

EID: 84858293578     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2012.5     Document Type: Short Survey

References (10)

1. Garnick, M. B. & Mottet, N. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist. BJU Int. http://dx.http://dx.doi.org/10.1111/j.1464-410X.2011.10708.x.
2. McLeod, D. et al. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 58, 756-761 (2001).
3. Mongiat-Artus, P. & Teillac, P. Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer. Expert Opin. Pharmacother. 5, 2171-2179 (2004). (Pubitemid 39406118)
4. Klotz, L. et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 102, 1531-1538 (2008).
5. Crawford, E. D. et al. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J. Urol. 186, 889-897 (2011).
6. Tombal, B. et al. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur. Urol. 57, 836-842 (2010).
7. Schröder, F. H. et al. Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study. BJU Int. 106, 182-187 (2010).
8. Dreicer, R., Bajorin, D. F., McLeod, D. G., Petrylak, D. P. & Moul, J. W. New data, new paradigms for treating prostate cancer patients-VI: novel hormonal therapy approaches. Urology 78 (5 Suppl.), S494-S498 (2011).
9. Moul, J. W. Twenty-five year evolution of medical hormonal therapy for prostate cancer. BJU Int. 103, 145-146 (2009).
10. Ryan, C. J. & Tindall, D. J. Androgen receptor rediscovered: the new biology and targeting the androgen receptor therapeutically. J. Clin. Oncol. 29, 3651-3658 (2011).